Claris Lifesciences has received the letter from the Food and Drug Administration of United States of America (USFDA) stating it has completed the evaluation. The US FDA’s letter cited that it has completed evaluation of the company’s corrective action in response to the Warning Letter WL: 320-11-003, dated November 01, 2010. Based on their evaluation, the US FDA vide their letter dated August 14, 2012, confirmed that the violation(s) contained in the warning letter have been addressed.
The company had received 7 ANDAs approval across 4 products before the warning letter was issued, the company has filed for a total of 32 ANDAs across 21 products which includes niche products like profol and Iron Sucrose. The estimated market size of all products in the United States is about $1 billion.
The company has commercialized sales across 91 countries worldwide and has 1,228 product approvals out of which 207 are in the regulated market and has filed for 357 marketing authorizations under registration out of which 122 are in the regulated market.
| Company Name | CMP |
|---|---|
| Redington | 227.50 |
| Adani Enterprises | 2228.00 |
| Amrapali Industries | 17.36 |
| Rashi Peripheral | 474.40 |
| PDS | 294.40 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: